Overview: FXTAS Risk Profile TestIntroduction: The FXTAS Risk Profile Test tests for FMR1 gene mutations to assess risk for fragile X-associated tremor/ataxia syndrome, causing tremors or coordination issues, aiding in diagnosis. Affecting 1 in 3,000 males over 50, FXTAS poses diagnostic challenges due to late onset. Following 2023 American College of Medical Genetics (ACMG) guidelines, it uses PCR/fragment analysis for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, risk assessment, and improving outcomes in neurology.
Other Names: FMR1 FXTAS Test, Tremor-Ataxia Risk Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: FXTAS research began in the 2000s with research by Hagerman, who linked FMR1 premutations to tremor/ataxia. PCR/fragment analysis advancements by Applied Biosystems improved detection, surpassing earlier Southern blot methods.
Purpose: Detects FMR1 mutations to assess FXTAS risk, guides supportive therapy, and evaluates patients with tremors, aiming to manage symptoms.
Test Parameters: FMR1 mutation status
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of neurological issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document tremors or coordination issues. Include current medications or family history of fragile X disorders.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., ataxia), and sample collection risks.
Procedural Considerations: Uses PCR/fragment analysis to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutations indicate risk, guiding therapy. Early management might prevent worsening, while untreated cases lead to disability. Normal results may require MRI.
Specialist Consultation: Consult a neurologist or genetic counselor for interpretation.
Additional Supporting Tests: Brain imaging, neurological exam, or genetic panel to confirm diagnosis.
Test Limitations: Indicates risk only; correlation with symptoms needed. False negatives possible with mosaicism.
References: ACMG Guidelines, 2023; Neurology, Hagerman RJ, 2022.
